Drug activates brain activity subdued by Tau protein

Using a mouse model, researchers report that rolofylline, a drug developed for patients with acute heart failure and renal dysfunction, restored spatial memory deficits and normalized synaptic transmission when administered to mice expressing human Tau, suggesting that rolofylline may increase neural activity in patients with Tau aggregation and delay the onset and progression of some neurodegenerative diseases. - Read at PNAS.org

Article #16-03119: “Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280,” by Frank J.A. Dennissen, Marta Anglada-Huguet, Astrid Sydow, Eckhard Mandelkow, and Eva-Maria Mandelkow.